FMN riboswitch modulator
Infectious diseases
Pre-clinicalHit Identification
Key Facts
About Acellera
Acellera's mission is to transform drug discovery into a high-accuracy, computable task by developing algorithms that automate the process. Founded in 2016, the company has built a robust technology stack, including the QuantumBind® platform and open-source tools like ACEMD, OpenMM, and ACEGEN, backed by over 18 years of computational know-how and thousands of academic citations. While currently a private company with no external investment, Acellera is developing an internal pipeline of drug candidates and plans to raise funding in 2026 to scale its ambitious goals.
View full company profileTherapeutic Areas
Other Infectious diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Next-generation mRNA Vaccines | BioNTech | Phase 1 |
| Genetic Molecular Tests | Eurobio Scientific | Commercial |
| LEAPS Technology | CEL-SCI | Pre-clinical |
| Platform Vaccine Applications | Chimeron Bio | Discovery |